Ilya Tsimafeyeu/bucare.org
Jun 26, 2025, 08:50
Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma
Ilya Tsimafeyeu, Director at the Bureau of Cancer Research, shared a post on Facebook:
“Long-term follow-up has shown promising results for the combination of bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma.
I treated two patients with HLRCC-related kidney cancer, and both experienced durable partial responses to bev plus erlo.
Additionally, I prescribed this combination to a patient with metastatic FH-deficient papillary RCC, who achieved a complete response. I can strongly recommend!”
Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer
Journal: NEJM
Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan
More posts featuring Ilya Tsimafeyeu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 16, 2025, 20:13
Jul 16, 2025, 17:55
Jul 16, 2025, 17:38
Jul 16, 2025, 17:37
Jul 16, 2025, 17:04
Jul 16, 2025, 16:51